| Cat. No. |
Product Name |
Information |
| PC-24898 |
TNI-97
HDAC6 inhibitor
|
TNI-97 is a potent, highly selective and orally bioavailable HDAC6 inhibitor with IC50 of 0.2 nM. |
| PC-24776 |
ITF3107
HDAC6 inhibitor
|
ITF3107 is a potent, selective HDAC6 inhibitor with IC50 of 5 nM, >70-fold more selective for HDAC6over HDAC1/2/3. |
| PC-24775 |
ACY-1083
HDAC6 inhibitor
|
ACY-1083 is a potent, selective and brain-penetrating HDAC6 inhibitor with IC50 of 3 nM, >250-fold more selective for HDAC6 than all other classes of HDAC isoforms. |
| PC-24774 |
ITF3985
HDAC6 inhibitor
|
ITF39856 (ITF-3985) is a potent, selective HDAC6 inhibitor with IC50 of 5 nM, >500-fold selective over HDAC1/2/3. |
| PC-24698 |
PAT-1102
HDAC inhibitor
|
PAT-1102 (FNDR-20123) is a novel, potent, orally available HDAC inhibitor with IC50 of 3 nM in cell-free HDAC enzymatic assays, also inhibits Plasmodium HDAC with IC50 of 31 nM. |
| PC-24425 |
DDI199
HDAC/ChE/MAO inhibitor
|
DDI199 (Contilistat) is a novel multi-target molecule by linking Contilisant and Vorinostat (SAHA), inhibits histone deacetylases (HDACs), monoamine oxidases (MAOs) and cholinesterases (ChEs), and modulate histamine H3 (H3R) and Sigma 1 Receptor (S1R) receptors, shows anti-tumor activity against glioma stem cells (GSCs). |
| PC-24229 |
HDAC6 inhibitor FDR2
HDAC6 inhibitor
|
HDAC6 inhibitor FDR2 is a selective small molecule HDAC6 inhibitor with IC50 of 50.8 nM, shows >100-fold selectivity over HDAC1. |
| PC-24228 |
HDAC6 inhibitor DR-3
HDAC6 inhibitor
|
HDAC6 inhibitor DR-3 is a selective small molecule HDAC6 inhibitor with IC50 of 78.1 nM, shows 100-fold selectivity over HDAC1. |
| PC-24027 |
SR-4370
HDAC inhibitor
|
SR-4370 is a novel HDAC inhibitor with IC50 of 0.13/0.5/0.006/3.4/2.3 μM for HDAC1/2/3/6/8, respectively, also is a latency-reversing agent (LRA) for reactivation of latent HIV-1. |
| PC-23991 |
IHCH9033
class I HDAC inhibitor
|
IHCH9033 is a selective, triazole-containing class I HDAC inhibitor, exhibits an increased antitumor effect in FLT3-ITD AML through effectively eliminating leukemia burden and overcoming resistance to FLT3i. |
| PC-23970 |
RG2833
HDAC1/3 inhibitor
|
RG2833 is a potent, orally bioavailable, brain-penetrant histone deacetylase HDAC1/3 inhibitor with IC50 of 60/50 mM respectively. |
| PC-23806 |
NSC3852
HDAC inhibitor
|
NSC3852 is a small molecule inhibitor of histone deacetylase (HDAC) with cell differentiation and antiproliferative activity in human breast cancer cells, synergistically enhances the cytotoxicity of olaparib in oral squamous cell carcinoma. |
